Defining the biological basis of radiomic phenotypes in lung cancer

eLife

Volumn 6, Issue , 2017, Pages

  Grossmann, Patrick ^a,b   Stringfield, Olya ^c   El Hachem, Nehme ^d   Bui, Marilyn M ^c   Velazquez, Emmanuel Rios ^a   Parmar, Chintan ^a,e   Leijenaar, Ralph T H ^e   Haibe Kains, Benjamin ^f,g   Lambin, Philippe ^e   Gillies, Robert J ^c   Aerts, Hugo J W L ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; CD3 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; RNA POLYMERASE; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN PROTEIN LIGASE COP1; TUMOR MARKER;

ALGORITHM; ARTICLE; AUTOPHAGY; CANCER STAGING; CARCINOGENESIS; CLINICAL DECISION MAKING; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MULTIFACTOR DIMENSIONALITY REDUCTION; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHENOTYPE; RADIOLOGY; RADIOMICS; SIGNAL TRANSDUCTION; ADENOCARCINOMA; DIAGNOSTIC IMAGING; LUNG TUMOR; METABOLISM; PATHOLOGY; PROCEDURES; PROGNOSIS; RADIOMETRY; SQUAMOUS CELL CARCINOMA; X-RAY COMPUTED TOMOGRAPHY;

ADENOCARCINOMA; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CLINICAL DECISION-MAKING; DIAGNOSTIC IMAGING; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; PHENOTYPE; PROGNOSIS; RADIOMETRY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85029436472     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.23421     Document Type: Article

References (78)

1. Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, Cavalho S, Bussink J, Monshouwer R, Haibe-Kains B, Rietveld D, Hoebers F, Rietbergen MM, Leemans CR, Dekker A, Quackenbush J, Gillies RJ, Lambin P. 2014. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nature Communications 5:4006. doi: 10.1038/ncomms5006, PMID: 24892406
2. Aerts HJ. 2016. The potential of radiomic-based phenotyping in precision medicine: a review. JAMA Oncology2:1636. doi: 10.1001/jamaoncol.2016.2631, PMID: 27541161
3. Aerts HJ, Grossmann P, Tan Y, Oxnard GG, Rizvi N, Schwartz LH, Zhao B. 2016. Defining a radiomic response phenotype: a pilot study using targeted therapy in NSCLC. Scientific Reports 6:33860. doi: 10.1038/srep33860, PMID: 27645803
4. Ahrendt SA, Hu Y, Buta M, McDermott MP, Benoit N, Yang SC, Wu L, Sidransky D. 2003. p53 mutations and survival in stage I non-small-cell lung Cancer: results of a prospective study. JNCI Journal of the National Cancer Institute 95:961-970. doi: 10.1093/jnci/95.13.961, PMID: 12837832
5. Balagurunathan Y, Gu Y, Wang H, Kumar V, Grove O, Hawkins S, Kim J, Goldgof DB, Hall LO, Gatenby RA, Gillies RJ. 2014. Reproducibility and prognosis of quantitative features extracted from CT Images. Translational Oncology 7:72-87. doi: 10.1593/tlo.13844, PMID: 24772210
6. Baldi A, De Luca A, Esposito V, Campioni M, Spugnini EP, Citro G. 2011. Tumor suppressors and cell-cycle proteins in lung Cancer. Pathology Research International 2011:1-12. doi: 10.4061/2011/605042, PMID: 22007345
7. Benjamini Y, Hochberg Y. 1995. Controlling the False Discovery Rate: a Practical and Powerful Approach to multiple testing. Journal of the Royal Statistical Society. Series B, Statistical Methodology 57:289-300. doi: 10.2307/2346101
8. Bergmann S, Ihmels J, Barkai N. 2003. Iterative signature algorithm for the analysis of large-scale gene expression data. Physical Review E 67:031902. doi: 10.1103/PhysRevE.67.031902, PMID: 12689096
9. Bradley AP. 1997. The use of the area under the ROC curve in the evaluation of machine learning algorithms. Pattern Recognition 30:1145-1159. doi: 10.1016/S0031-3203(96)00142-2
10. Bryant JL, Meredith SL, Williams KJ, White A. 2014. Targeting hypoxia in the treatment of small cell lung Cancer. Lung Cancer 86:126-132. doi: 10.1016/j.lungcan.2014.08.003, PMID: 25201720
11. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, Chan WK, Li HN, Liu CC, Singh S, Chen WJ, Chen JJ, Yang PC. 2007. A five-gene signature and clinical outcome in non-small-cell lung Cancer. New England Journal of Medicine 356:11-20. doi: 10.1056/NEJMoa060096, PMID: 17202451
12. Choi ER, Lee HY, Jeong JY, Choi YL, Kim J, Bae J, Lee KS, Shim YM. 2016. Quantitative image variables reflect the intratumoral pathologic heterogeneity of lung adenocarcinoma. Oncotarget 7:67302-67313. doi: 10.18632/ oncotarget.11693, PMID: 27589833
13. Chong Y, Kim JH, Lee HY, Ahn YC, Lee KS, Ahn MJ, Kim J, Shim YM, Han J, Choi YL. 2014. Quantitative CT variables enabling response prediction in neoadjuvant therapy with EGFR-TKIs: are they different from those in neoadjuvant concurrent chemoradiotherapy? PLoS One 9:e88598. doi: 10.1371/journal.pone.0088598, PMID: 24586348
14. Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, Marsden P, Ahmad S, Landau D. 2013. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung Cancer associated with response and survival after chemoradiotherapy? Journal of Nuclear Medicine 54:19-26. doi: 10.2967/jnumed.112.107375, PMID: 23204495
15. Coroller TP, Grossmann P, Hou Y, Rios Velazquez E, Leijenaar RT, Hermann G, Lambin P, Haibe-Kains B, Mak RH, Aerts HJ. 2015. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiotherapy and Oncology 114:345-350. doi: 10.1016/j.radonc.2015.02.015, PMID: 25746350
16. Csárdi G, Kutalik Z, Bergmann S. 2010. Modular analysis of gene expression data with R. Bioinformatics 26:1376-1377. doi: 10.1093/bioinformatics/btq130, PMID: 20371495
17. De Jay N, Papillon-Cavanagh S, Olsen C, El-Hachem N, Bontempi G, Haibe-Kains B, Jay ND. 2013. mRMRe: an R package for parallelized mRMR ensemble feature selection. Bioinformatics 29:2365-2368. doi: 10.1093/bioinformatics/btt383, PMID: 23825369
18. Denny WA. 2010. Hypoxia-activated prodrugs in Cancer therapy: progress to the clinic. Future Oncology 6:419-428. doi: 10.2217/fon.10.1, PMID: 20222798
19. Diehn M, Nardini C, Wang DS, McGovern S, Jayaraman M, Liang Y, Aldape K, Cha S, Kuo MD. 2008. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. PNAS 105:5213-5218. doi: 10.1073/pnas.0801279105, PMID: 18362333
20. Doroshow JH, Kummar S. 2014. Translational research in oncology-10 years of progress and future prospects. Nature Reviews Clinical Oncology 11:649-662. doi: 10.1038/nrclinonc.2014.158, PMID: 25286976
21. Fawcett T. 2006. An introduction to ROC analysis. Pattern Recognition Letters 27:861-874. doi: 10.1016/j.patrec.2005.10.010
22. Fisher R, Pusztai L, Swanton C. 2013. Cancer heterogeneity: implications for targeted therapeutics. British Journal of Cancer 108:479-485. doi: 10.1038/bjc.2012.581, PMID: 23299535
23. Fried DV, Tucker SL, Zhou S, Liao Z, Mawlawi O, Ibbott G, Court LE. 2014. Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung Cancer. International Journal of Radiation Oncology*Biology*Physics 90:834-842. doi: 10.1016/j.ijrobp.2014.07.020, PMID: 25220716
24. Ganeshan B, Abaleke S, Young RC, Chatwin CR, Miles KA. 2010. Texture analysis of non-small cell lung Cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage. Cancer Imaging 10:137-143. doi: 10.1102/1470-7330.2010.0021, PMID: 20605762
25. Ganeshan B, Panayiotou E, Burnand K, Dizdarevic S, Miles K. 2012. Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. European Radiology 22:796-802. doi: 10.1007/s00330-011-2319-8, PMID: 22086561
26. Ganeshan B, Goh V, Mandeville HC, Ng QS, Hoskin PJ, Miles KA. 2013. Non-small cell lung Cancer: histopathologic correlates for texture parameters at CT. Radiology 266:326-336. doi: 10.1148/radiol.12112428, PMID: 23169792
27. Gautier L, Cope L, Bolstad BM, Irizarry RA. 2004. Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20:307-315. doi: 10.1093/bioinformatics/btg405, PMID: 14960456
28. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine 366:883-892. doi: 10.1056/NEJMoa1113205, PMID: 22397650
29. Gevaert O, Xu J, Hoang CD, Leung AN, Xu Y, Quon A, Rubin DL, Napel S, Plevritis SK. 2012. Non-small cell lung Cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data-methods and preliminary results. Radiology 264:387-396. doi: 10.1148/radiol.12111607, PMID: 22723499
30. Gevaert O, Mitchell LA, Achrol AS, Xu J, Echegaray S, Steinberg GK, Cheshier SH, Napel S, Zaharchuk G, Plevritis SK. 2014. Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. Radiology 273:168-174. doi: 10.1148/radiol.14131731, PMID: 24827998
31. Gillies RJ, Anderson AR, Gatenby RA, Morse DL. 2010. The biology underlying molecular imaging in oncology: from genome to anatome and back again. Clinical Radiology 65:517-521. doi: 10.1016/j.crad.2010.04.005, PMID: 20541651
32. Gillies RJ, Kinahan PE, Hricak H. 2016. Radiomics: images are more than Pictures, they are data. Radiology 278: 563-577. doi: 10.1148/radiol.2015151169, PMID: 26579733
33. Grossmann P, Gutman DA, Dunn WD, Holder CA, Aerts HJ. 2016. Imaging-genomics reveals driving pathways of MRI derived volumetric tumor phenotype features in glioblastoma. BMC Cancer 16:611. doi: 10.1186/s12885-016-2659-5, PMID: 27502180
34. Grossmann P, Narayan V, Chang K, Rahman R, Abrey L, Reardon DA, Schwartz LH, Wen PY, Alexander BM, Huang R, Aerts H. 2017. Quantitative Imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with Bevacizumab. Neuro-Oncology. doi: 10.1093/neuonc/nox092, PMID: 28499022
35. Grove O, Berglund AE, Schabath MB, Aerts HJ, Dekker A, Wang H, Velazquez ER, Lambin P, Gu Y, Balagurunathan Y, Eikman E, Gatenby RA, Eschrich S, Gillies RJ. 2015. Quantitative computed tomographic descriptors associate tumor shape complexity and intratumor heterogeneity with prognosis in lung adenocarcinoma. PLoS One 10:e0118261. doi: 10.1371/journal.pone.0118261, PMID: 25739030
36. Gutman DA, Dunn WD, Grossmann P, Cooper LA, Holder CA, Ligon KL, Alexander BM, Aerts HJ. 2015. Somatic mutations associated with MRI-derived volumetric features in glioblastoma. Neuroradiology 57:1227-1237. doi: 10.1007/s00234-015-1576-7, PMID: 26337765
37. Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. 1982. Evaluating the yield of medical tests. JAMA: The Journal of the American Medical Association 247:2543-2546. doi: 10.1001/jama.1982.03320430047030, PMID: 7069920
38. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC, Grosveld F, Philipsen S. 2010. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One 5:e10312. doi: 10.1371/journal.pone.0010312, PMID: 20421987
39. Hsu YC, Yuan S, Chen HY, Yu SL, Liu CH, Hsu PY, Wu G, Lin CH, Chang GC, Li KC, Yang PC. 2009. A four-gene signature from NCI-60 cell line for survival prediction in non-small cell lung Cancer. Clinical Cancer Research15:7309-7315. doi: 10.1158/1078-0432.CCR-09-1572, PMID: 19920108
40. Huang YQ, Liang CH, He L, Tian J, Liang CS, Chen X, Ma ZL, Liu ZY. 2016a. Development and Validation of a Radiomics Nomogram for Preoperative prediction of Lymph Node Metastasis in Colorectal Cancer. Journal of Clinical Oncology 34:2157-2164. doi: 10.1200/JCO.2015.65.9128, PMID: 27138577
41. Huang Y, Liu Z, He L, Chen X, Pan D, Ma Z, Liang C, Tian J, Liang C. 2016b. Radiomics signature: a potential biomarker for the prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell lung Cancer. Radiology 281:947-957. doi: 10.1148/radiol.2016152234, PMID: 27347764
42. Hänzelmann S, Castelo R, Guinney J. 2013. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14:7. doi: 10.1186/1471-2105-14-7, PMID: 23323831
43. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249-264. doi: 10.1093/biostatistics/4.2.249, PMID: 12925520
44. Joshi-Tope G, Gillespie M, Vastrik I, D’Eustachio P, Schmidt E, de Bono B, Jassal B, Gopinath GR, Wu GR, Matthews L, Lewis S, Birney E, Stein L. 2005. Reactome: a knowledgebase of biological pathways. Nucleic Acids Research 33:D428-D432. doi: 10.1093/nar/gki072, PMID: 15608231
45. Kobayashi S, Yoneda-Kato N, Itahara N, Yoshida A, Kato JY. 2013. The COP1 E3-ligase interacts with FIP200, a key regulator of mammalian autophagy. BMC Biochemistry 14:1. doi: 10.1186/1471-2091-14-1, PMID: 232 89756
46. Kumar V, Gu Y, Basu S, Berglund A, Eschrich SA, Schabath MB, Forster K, Aerts HJ, Dekker A, Fenstermacher D, Goldgof DB, Hall LO, Lambin P, Balagurunathan Y, Gatenby RA, Gillies RJ. 2012. Radiomics: the process and the challenges. Magnetic Resonance Imaging 30:1234-1248. doi: 10.1016/j.mri.2012.06.010, PMID: 22898692
47. Kuo MD, Jamshidi N. 2014. Behind the numbers: decoding molecular phenotypes with radiogenomics-guiding principles and technical considerations. Radiology 270:320-325. doi: 10.1148/radiol.13132195, PMID: 24471381
48. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, Zegers CM, Gillies R, Boellard R, Dekker A, Aerts HJ. 2012. Radiomics: extracting more information from medical images using advanced feature analysis. European Journal of Cancer 48:441-446. doi: 10.1016/j.ejca.2011.11.036, PMID: 22257792
49. Leijenaar RT, Carvalho S, Velazquez ER, van Elmpt WJ, Parmar C, Hoekstra OS, Hoekstra CJ, Boellaard R, Dekker AL, Gillies RJ, Aerts HJ, Lambin P. 2013. Stability of FDG-PET radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncologica 52:1391-1397. doi: 10.3109/0284186X.2013. 812798, PMID: 24047337
50. Li H, Zhu Y, Burnside ES, Drukker K, Hoadley KA, Fan C, Conzen SD, Whitman GJ, Sutton EJ, Net JM, Ganott M, Huang E, Morris EA, Perou CM, Ji Y, Giger ML. 2016. MR Imaging Radiomics signatures for predicting the risk of breast Cancer recurrence as given by Research Versions of MammaPrint, Oncotype DX, and PAM50 gene assays. Radiology 281:382-391. doi: 10.1148/radiol.2016152110, PMID: 27144536
51. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. 2011. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27:1739-1740. doi: 10.1093/bioinformatics/btr260, PMID: 21546393
52. Liu Y, Kim J, Balagurunathan Y, Li Q, Garcia AL, Stringfield O, Ye Z, Gillies RJ. 2016. Radiomic features are associated with EGFR mutation status in lung adenocarcinomas. Clinical Lung Cancer 17:441-448. doi: 10.1016/j.cllc.2016.02.001, PMID: 27017476
53. Mattonen SA, Palma DA, Johnson C, Louie AV, Landis M, Rodrigues G, Chan I, Etemad-Rezai R, Yeung TP, Senan S, Ward AD. 2016. Detection of local Cancer recurrence after stereotactic ablative Radiation therapy for lung Cancer: physician Performance Versus Radiomic Assessment. International Journal of Radiation Oncology*Biology*Physics 94:1121-1128. doi: 10.1016/j.ijrobp.2015.12.369, PMID: 26907916
54. Menendez D, Shatz M, Resnick MA. 2013. Interactions between the tumor suppressor p53 and immune responses. Current Opinion in Oncology 25:85-92. doi: 10.1097/CCO.0b013e32835b6386, PMID: 23150340
55. Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, van Beek E. 2012. The 7th lung Cancer TNM classification and staging system: review of the changes and implications. World Journal of Radiology 4:0. doi: 10.4329/wjr.v4.i4. 128, PMID: 22590666
56. Nicolasjilwan M, Hu Y, Yan C, Meerzaman D, Holder CA, Gutman D, Jain R, Colen R, Rubin DL, Zinn PO, Hwang SN, Raghavan P, Hammoud DA, Scarpace LM, Mikkelsen T, Chen J, Gevaert O, Buetow K, Freymann J, Kirby J, et al. 2015. Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients. Journal of Neuroradiology 42:212-221. doi: 10.1016/j.neurad.2014.02.006, PMID: 24997477
57. O’Connor JP, Rose CJ, Waterton JC, Carano RA, Parker GJ, Jackson A, O’Connor JPB. 2015. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clinical Cancer Research21:249-257. doi: 10.1158/1078-0432.CCR-14-0990, PMID: 25421725
58. O’Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, deSouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, et al. 2017. Imaging biomarker roadmap for Cancer studies. Nature Reviews Clinical Oncology 14:169-186. doi: 10.1038/nrclinonc.2016.162, PMID: 27725679
59. Pardoll DM. 2012. The blockade of immune checkpoints in Cancer immunotherapy. Nature Reviews Cancer 12: 252-264. doi: 10.1038/nrc3239, PMID: 22437870
60. Parmar C, Leijenaar RT, Grossmann P, Rios Velazquez E, Bussink J, Rietveld D, Rietbergen MM, Haibe-Kains B, Lambin P, Aerts HJ. 2015a. Radiomic feature clusters and prognostic signatures specific for lung and Head & Neck Cancer. Scientific Reports 5:11044. doi: 10.1038/srep11044, PMID: 26251068
61. Parmar C, Grossmann P, Rietveld D, Rietbergen MM, Lambin P, Aerts HJ. 2015b. Radiomic machine-learning Classifiers for prognostic biomarkers of head and neck cancer. Frontiers in Oncology 5:272. doi: 10.3389/fonc.2015.00272, PMID: 26697407
62. Pencina MJ, D’Agostino RB. 2004. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Statistics in Medicine 23:2109-2123. doi: 10.1002/sim.1802, PMID: 15211606
63. Postow MA, Callahan MK, Wolchok JD. 2015. Immune checkpoint blockade in Cancer therapy. Journal of Clinical Oncology 33:1974-1982. doi: 10.1200/JCO.2014.59.4358, PMID: 25605845
64. R Development Core Team. 2013. R: A Language and Environment for Statistical Computin. Austria, R Foundation for Statistical Computing. http://www.R-project.org
65. Rabbani MG, Hossain SA, Islam KK, Uddin SN. 2014. Constitutive photomorphogensis Protein1 (COP1) mediated p53 pathway and its oncogenic role. Biomedical Research and Therapy 1:142-151. doi: 10.7603/s40730-014-0022-5
66. Rizzo S, Petrella F, Buscarino V, De Maria F, Raimondi S, Barberis M, Fumagalli C, Spitaleri G, Rampinelli C, De Marinis F, Spaggiari L, Bellomi M. 2016. CT Radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell Lung cancer. European Radiology 26:32-42. doi: 10.1007/s00330-015-3814-0, PMID: 25956936
67. Rutman AM, Kuo MD. 2009. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. European Journal of Radiology 70:232-241. doi: 10.1016/j.ejrad.2009.01.050, PMID: 19303233
68. Schröder MS, Culhane AC, Quackenbush J, Haibe-Kains B. 2011. Survcomp: an R/Bioconductor package for performance assessment and comparison of survival models. Bioinformatics 27:3206-3208. doi: 10.1093/bioinformatics/btr511
69. Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chen X, Chan BK, Matcuk GR, Barry CT, Chang HY, Kuo MD. 2007. Decoding global gene expression programs in liver Cancer by noninvasive imaging. Nature Biotechnology 25: 675-680. doi: 10.1038/nbt1306, PMID: 17515910
70. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, Curtis C, Watts C, Tavaré S. 2013. Intratumor heterogeneity in human glioblastoma reflects Cancer evolutionary dynamics. PNAS 110:4009-4014. doi: 10.1073/pnas.1219747110, PMID: 23412337
71. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. PNAS 102:15545-15550. doi: 10.1073/pnas.0506580102, PMID: 16199517
72. Theodoridis S, Koutroumbas K. 2008. Fourth Edition. Pattern Recognition. Academic Press.
73. Whitlock MC. 2005. Combining probability from independent tests: the weighted Z-method is superior to Fisher’s approach. Journal of Evolutionary Biology 18:1368-1373. doi: 10.1111/j.1420-9101.2005.00917.x, PMID: 16135132
74. Win T, Miles KA, Janes SM, Ganeshan B, Shastry M, Endozo R, Meagher M, Shortman RI, Wan S, Kayani I, Ell PJ, Groves AM. 2013. Tumor heterogeneity and permeability as measured on the CT component of PET/CT predict survival in patients with non-small cell lung Cancer. Clinical Cancer Research 19:3591-3599. doi: 10.1158/1078-0432.CCR-12-1307, PMID: 23659970
75. Wolchok JD, Saenger Y. 2008. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. The Oncologist 13 Suppl 4:2-9. doi: 10.1634/theoncologist.13-S4-2, PMID: 19001145
76. Yoon HJ, Sohn I, Cho JH, Lee HY, Kim JH, Choi YL, Kim H, Lee G, Lee KS, Kim J. 2015. Decoding tumor phenotypes for ALK, ROS1, and RET Fusions in lung adenocarcinoma using a Radiomics Approach. Medicine94:e1753. doi: 10.1097/MD.0000000000001753, PMID: 26469915
77. Yuan BZ, Jefferson AM, Popescu NC, Reynolds SH. 2004. Aberrant gene expression in human non small cell lung carcinoma cells exposed to demethylating agent 5-aza-2'-deoxycytidine. Neoplasia 6:412-419. doi: 10.1593/neo.03490, PMID: 15256063
78. Zhao B, Tan Y, Tsai WY, Qi J, Xie C, Lu L, Schwartz LH. 2016. Reproducibility of radiomics for deciphering tumor phenotype with imaging. Scientific Reports 6:23428. doi: 10.1038/srep23428, PMID: 27009765